 Frequency Therapeutics Inc NASDAQ: FREQ has announced that four additional sensorineural hearing loss SNHL subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements. The patients were evaluated 8 to 12 months following initial dosing. 